Robyn Mitchell
Overview
Explore the profile of Robyn Mitchell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yau R, Mitchell R, Afzal A, George T, Siddiqullah S, Bharadwaj A, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Dec;
3(11):102288.
PMID: 39649821
Background: Multidisciplinary cardiogenic shock (CS) programs have been associated with improved outcomes, yet practical guidance for developing a CS program is lacking. Methods: A survey on CS program development and...
2.
Lee D, McGill E, Pelude L, Mitchell R, Comeau J, Frenette C, et al.
Antimicrob Steward Healthc Epidemiol
. 2024 Oct;
4(1):e175.
PMID: 39450098
Objective: This study describes trends in COVID-19 hospitalizations and healthcare-associated (HA) COVID-19 in Canada among pediatric (age <18 years) patients during pre-Omicron and Omicron-dominant periods. Design: Prospective surveillance for COVID-19...
3.
Court R, Swallow V, El-Yousfi S, Gray-Burrows K, Sotir F, Wheeler G, et al.
Arch Dis Child
. 2024 Aug;
109(10):826-835.
PMID: 39142825
Background: The use of patient-facing health technologies to manage long-term conditions (LTCs) is increasing; however, children and young people (CYP) may have preferences about health technologies which they interact or...
4.
Lerminiaux N, Mitchell R, Katz K, Fakharuddin K, McGill E, Mataseje L
Microb Genom
. 2024 Jun;
10(6).
PMID: 38896471
Carbapenems are last-resort antibiotics for treatment of infections caused by multidrug-resistant , but carbapenem resistance is a rising global threat due to the acquisition of carbapenemase genes. Oxacillinase-48 ( )-type...
5.
Mitchell R, Lee D, Pelude L, Comeau J, Conly J, Ellis C, et al.
Can Commun Dis Rep
. 2024 Mar;
49(7-8):351-357.
PMID: 38455882
Background: Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data...
6.
Qaddoura A, Bartoszko J, Mitchell R, Frenette C, Johnston L, Mertz D, et al.
J Assoc Med Microbiol Infect Dis Can
. 2024 Jan;
8(4):272-282.
PMID: 38250620
Background: Extracorporeal membrane oxygenation (ECMO) for COVID-19 across Canada has not been well-described. We studied trends for patients with COVID-19-related acute respiratory distress syndrome who received ECMO. Methods: Multicentre retrospective...
7.
Lerminiaux N, Mitchell R, Bartoszko J, Davis I, Ellis C, Fakharuddin K, et al.
Antimicrob Agents Chemother
. 2023 Nov;
67(12):e0086023.
PMID: 37971242
Carbapenems are considered last-resort antibiotics for the treatment of infections caused by multidrug-resistant , but carbapenem resistance due to acquisition of carbapenemase genes is a growing threat that has been...
8.
Mitchell R, Cayen J, Thampi N, Frenette C, Bartoszko J, Choi K, et al.
JAMA Netw Open
. 2023 Apr;
6(4):e239050.
PMID: 37079304
Importance: Trends in COVID-19 severe outcomes have significant implications for the health care system and are key to informing public health measures. However, data summarizing trends in severe outcomes among...
9.
Choi K, Du T, Silva A, Golding G, Pelude L, Mitchell R, et al.
Infect Control Hosp Epidemiol
. 2022 Aug;
44(7):1180-1183.
PMID: 35978535
The coronavirus disease 2019 (COVID-19) pandemic has placed significant burden on healthcare systems. We compared infection (CDI) epidemiology before and during the pandemic across 71 hospitals participating in the Canadian...
10.
Bartoszko J, Mitchell R, Katz K, Mulvey M, Mataseje L
Microbiol Spectr
. 2022 Aug;
10(4):e0097522.
PMID: 35950772
Data regarding the epidemiology of extensively drug-resistant (XDR) carbapenemase-producing (CPE) in Canada are scarce. Among CPE patients identified by the Canadian Nosocomial Infection Surveillance Program, the following were each significantly...